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Abstract
Internalization of receptor proteins after interacting with specific ligands has been proposed to facilitate siRNA delivery into
the target cells via receptor-mediated siRNA transduction. In this study, we demonstrated a novel method of vasopressin V2
receptor (V2R)-mediated siRNA delivery against AQP2 in primary cultured inner medullary collecting duct (IMCD) cells of rat
kidney. We synthesized the dDAVP conjugated with nine D-arginines (dDAVP-9r) as a peptide carrier for siRNA delivery. The
structure of synthetic peptide carrier showed two regions (i.e., ligand domain to V2R (dDAVP) and siRNA carrying domain
(nine D-arginine)) bisected with a spacer of four glycines. The results revealed that 1) synthesized dDAVP-9r peptides
formed a stable polyplex with siRNA; 2) siRNA/dDAVP-9r polyplex could bind to the V2R of IMCD cells and induced AQP2
phosphorylation (Ser 256); 3) siRNA/dDAVP-9r polyplex was stable in response to the wide range of different osmolalities,
pH levels, or to the RNases; 4) fluorescein-labeled siRNA was delivered into V2R-expressing MDCK and LLC-PK1 cells by
siRNA/dDAVP-9r polyplex, but not into the V2R-negative Cos-7 cells; and 5) AQP2-siRNA/dDAVP-9r polyplex effectively
delivered siRNA into the IMCD cells, resulting in the significant decrease of protein abundance of AQP2, but not AQP4.
Therefore, for the first time to our knowledge, we demonstrated that V2R-mediated siRNA delivery could be exploited to
deliver specific siRNA to regulate abnormal expression of target proteins in V2R-expressing kidney cells. The methods could
be potentially used in vivo to regulate abnormal expression of proteins associated with disease conditions in the V2R-
expressing kidney cells.
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Introduction
RNA interference (RNAi) technology has been emerged as a
potential therapeutic tool in gene therapy, since small interfering
RNA (siRNA) targeting a specific gene could regulate abnormal
expression of target proteins associated with disease conditions
[1,2]. However, cell- or tissue-type specificity of siRNA delivery is
one of the major obstacles in RNAi therapeutics and hence
siRNA-containing nanoparticles with high target-specificity is
required to overcome the non-specific delivery in the systemic
environment. Recent studies have suggested that peptide carriers,
based on the receptor internalization after interaction between
receptors and specific ligands, could be exploited for establishing a
reliable method of specific delivery of siRNAs. Kumar and his
colleagues demonstrated that peptide carrier named as RGV-nine
D-arginine (RGV-9r) was able to deliver siRNA into mouse
neuronal cells via an interaction with acetylcholine receptor of the
plasma membrane [3]. RVG-9r contained nine D-arginines to
form a complex with siRNA via an electrostatic interaction.
Subramanya et al. also demonstrated that siRNA delivery using a
peptide carrier successfully suppressed dengue viral replication and
virus-induced immune responses in dengue infection [4]. Addi-
tionally, the strategy of cell-type specific siRNA delivery reported
by Zhang et al. [5] demonstrated that siRNA tethered by folate-
conjugated oligodeoxynucleotide was delivered by the interaction
between folate and folate receptor.
In this study, we introduced a novel method of vasopressin V2
receptor (V2R)-mediated siRNA delivery in the kidney inner
medullary collecting duct (IMCD) cells using a specific peptide
ligand to V2R [i.e., 1-deamino-D-arginine vasopressin (dDAVP)].
Arginine vasopressin (AVP) is an anti-diuretic hormone, which
increases osmotic water permeability in the renal collecting ducts
via regulation of water channel protein aquaporin-2 (AQP2) [6].
Internalization of V2R into cytosol by clathrin-mediated endocy-
tosis has been well established after ligand binding. Bouley et al.
showed that endocytosis of the V2R was induced by vasopressin
stimulation in LLC-PK1 cells expressing V2R-GFP [7] or FLAG-
V2R [8], and hence it resulted in the decrease of V2R abundance
through lysosomal degradation [9]. MDCK cells expressing V2R-
GFP also showed V2R internalization in response to dDAVP
stimulation [10].
We synthesized the dDAVP conjugated with nine D-arginines
(dDAVP-9r) as a peptide carrier to deliver siRNA against AQPs
into the IMCD cells of rat kidney through V2R internalization.
We introduced, for the first time to our knowledge, a novel method
PLoS ONE | www.plosone.org 1 June 2012 | Volume 7 | Issue 6 | e40010of V2R-mediated siRNA delivery by demonstrating that 1)
synthesized dDAVP-9r peptides formed as a stable polyplex with
siRNA, 2) siRNA/dDAVP-9r polyplex could bind to the V2R of
IMCD cells and induced AQP2 phosphorylation (Ser 256), 3)
siRNA/dDAVP-9r polyplex was stable in response to the wide
range of different osmolalities, pH levels, or to the RNases; and 4)
siRNA/dDAVP-9r polyplex successfully delivered siRNA into the
primary cultured IMCD cells, resulting in the significant decrease
of protein abundance of AQP.
Results
Structure of dDAVP-9r Peptide and Formation of siRNA/
dDAVP-9r Polyplex
dDAVP-9r peptide was composed of three domains, i.e.,
dDAVP (V2R binding region), four glycines (spacer), and nine
D-arginines (siRNA binding region, Fig. 1A). By using the PEP-
FOLD resource, the structure of dDAVP-9r peptide was
investigated. The lowest energy model indicated loop conforma-
tion of dDAVP, which was followed by the helical moiety of nine-
arginine stretch with a linker of four glycines. This model showed a
high structural similarity of the dDAVP with the vasopressin
peptide (CYFQNC, 1jk4-b, Fig. 1A), suggesting that dDAVP
adopts proper folding for disulfide bond between mercaptopro-
pionyl–N-terminus and Cys5 residue. dDAVP binds to V2R, and
the domain of nine D-arginines facilitates to form a complex with
siRNA molecules via an electrostatic interaction. Additionally, C-
terminus of the peptide was modified by amidation to neutralize
negative charge of C-terminus. Interaction between V2R and
dDAVP may be secured from the complex of nine D-arginines and
siRNA by the linker of four glycines.
To test the formation of siRNA/dDAVP-9r polyplex, electro-
phoretic mobility shift assay was performed. siRNA (100 pmol)
was incubated with dDAVP-9r peptides at the mole ratios of 1:0.1,
1:1, 1:2, 1:5, and 1:10 (siRNA:dDAVP-9r) in aqueous phase (PBS,
pH 7.4) for 15 min, respectively. siRNA was saturated with
dDAVP-9r peptides at mole ratio of 1:10, while dDAVP-9r
peptides were not made as a stable polyplex with siRNA at the
mole ratio of 1:0.1 (Fig. 1B).
Transduction of Fluorescein-labeled siRNA in
Endogenous V2R-expressing Cells Treated by FITC-siRNA/
dDAVP-9r Polyplex
To examine the transduction of FITC-siRNA into the cells,
V2R-expressing MDCK and LLC-PK1 cells [8,11,12] were
treated by FITC-siRNA/dDAVP-9r polyplex and analyzed by
flow cytometry (Fig. 2A). Cos-7 cells were also used as endogenous
V2R-negative cells [8] to determine the specificity of siRNA
uptake via the V2R. Cells were incubated with FITC-siRNA/
dDAVP-9r polyplex at the mole ratio of 1:10 or 1:40 for 1 h at
37uC. In addition, FITC-siRNA alone or FITC-siRNA/9r
polyplex (without dDAVP) were also tested at the mole ratio of
1:10 (siRNA:peptide). As shown in Fig. 2A, MDCK cells and
LLC-PK1 cells, which were incubated with FITC-siRNA (black
line) alone or FITC-siRNA/9r polyplex (green line) exhibited
much less FITC signals compared with the cells incubated with
FITC-siRNA/dDAVP-9r polyplex [1:10 mole ratio (red line) or
1:40 mole ratio (blue line)]. Importantly, no difference in cellular
uptake between FITC-siRNA/9r polyplex (1:10 mole ratio, green
line) and FITC-siRNA/dDAVP-9r polyplex (1:10 mole ratio, red
line) was found in Cos-7 cells, indicating that V2R mediated the
cellular uptake of siRNA. In contrast, all the examined cell lines
(MDCK, LLC-PK1, and Cos-7 cells) incubated with FITC-
siRNA/dDAVP-9r polyplex of 1:40 mole ratio showed increased
cellular uptake and this could be caused non-specifically by highly
positive surface charge of the polyplex, as previously demonstrated
[13,14].
Subcellular localization of the FITC-siRNA/dDAVP-9r poly-
plex in the MDCK cells was examined by laser scanning confocal
microscopy coupled with differential interference contrast (DIC)
images (Fig. 2B). Intracellular FITC signal was detected in the
MDCK cells treated by FITC-siRNA/dDAVP-9r polyplex (1:10
and 1:40 mole ratio in Fig. 2B), whereas the FITC signal was not
observed in the cells treated with FITC-siRNA alone or FITC-
siRNA/9r polyplex (1:10 mole ratio).
Stability of siRNA/dDAVP-9r Polyplex
The stability of siRNA-containing carrier against ribonucleases
(RNases) is required for the delivery of siRNA to the target cells or
tissues in vitro and in vivo safely. To examine the resistance of
siRNA/dDAVP-9r polyplex against RNases, the polyplex was
incubated with 5 mg/ml RNase A for 1 h or 6 h. As shown in
Fig. 3A, the naked siRNA was completely degradaded by RNase A
Figure 1. Structure of dDAVP-9r peptide and formation of
siRNA/dDAVP-9r polyplex. A) PEP-FOLD simulations give similar
structure folding of dDAVP region and vasopressin peptide. The lowest
energy structure of dDAVP-4 Gly-9 Arg peptide (dDAVP, light blue; 4
Gly, gray blue; and 9 Arg, blue) was aligned with vasopressin peptide
(CYFQNC, 1jk4-b, yellow). Disulfide bond of dDAVP was highlighted by
red and mercaptopropionyl N-terminal modification is indicated by
orange circle. B) Formation of siRNA/dDAVP-9r polyplex was examined
at the various mole ratios by electrophoretic mobility shift assay.
doi:10.1371/journal.pone.0040010.g001
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unaffected by RNase A at the mole ratio of 1:10 and 1:40. In
contrast, at the mole ratio of 1:5, siRNA content was slightly
decreased in the presence of RNase A (Fig. 3A).
The stability of siRNA/dDAVP-9r polyplex was also examined
in response to various conditions of different osmolalities or pH
levels (Fig. 3B). The polyplex was incubated in the absence or the
presence of 0.2% SDS, and siRNAs were electrophoresed on 2%
agarose gel containing EtBr (Fig. 3B). While at the mole ratio of
1:40 of siRNA/dDAVP-9r polyplex the electrostatic interaction
was not affected in response to different osmolalities (0, 100, 300,
600, and 1,200 mOsm/KgH2O), the polyplex at the mole ratio of
1:10 was partially disturbed by the osmolality over 600 mOsm/
KgH2O (observed at 600 and 1,200 mOsm/KgH2O, Fig. 3B). In
contrast, the formation of siRNA/dDAVP-9r polyplex at both
1:10 and 1:40 was unaffected by the tested pH levels (pH 5.5, 6.0,
6.5, 7.0, 7.5, and 8, Fig. 3B). After the treatment of SDS in each
lane, all the siRNA was intact (Fig. 3B).
In addition to the stability of polyplex, size and surface charge of
polyplex are also important factors for the cellular uptake. Particle
size of siRNA/dDAVP-9r polyplex was measured by light
scattering using Zetasizer. Z-average diameters of polyplex were
determined by dynamic light scattering at 25uC. siRNA/dDAVP-
9r polyplex at the mole ratio of 1:10 or 1:40 (siRNA:dDAVP-9r)
demonstrated different spectrum of particle diameters. siRNA/
dDAVP-9r polyplex at 1:10 mole ratio showed relatively constant
spectrum of diameters with an average particle diameter of
204667.7 nm. In contrast, the polyplex at 1:40 mole ratio
demonstrated wider spectrum of diameters with average particle
diameter of 395.76176.5 nm. The average particle diameter of
the polyplexes was determined by triplicate measurements in two
different aqueous suspension of each ratio. Additionally, zeta
potential of polyplex was measured to examine the surface charge
of polyplex at the mole ratio of 1:10 and 1:40. The values of
polyplex at the mole ratio of 1:10 were 11.1360.38 mV, while the
values of polyplex at the mole ratio of 1:40 were 17.960.79 mV.
Surface charge of each sample was also analyzed by triplicate
measurements in two different aqueous suspension of each ratio.
The results indicate that polyplex of 1:40 mole ratio possesses
highly positive surface charge, leading to non-specific interaction
with negatively charged plasma membrane of cells, as previously
demonstrated [13,14].
Interaction Between siRNA/dDAVP-9r Polyplex and V2R
in IMCD Cells
dDAVP-9r peptides formed the stable polyplex with siRNAs in
aqueous phase (Fig. 1). We examined whether the polyplex bind to
V2R expressed at the plasma membrane of IMCD cells. To study
the binding of siRNA/dDAVP-9r polyplex to V2R and their
ability to stimulate V2R, IMCD tubule suspension isolated from
rat kidneys were treated by dDAVP or dDAVP-9r for 3 min.
Figure 2. Internalization of siRNA/dDAVP-9r polyplex in V2R-expressing cells and V2R-negative cells. A) Cellular uptake of fluorescein-
labeled siRNA in V2R-expressing MDCK cells and LLC-PK1 cells, and V2R-negative Cos-7 cells was examined by flow cytometry. Black line: FITC-siRNA
alone; green line: FITC-siRNA/9r polyplex (1:10 mole ratio, siRNA:peptide); red line: FITC-siRNA/dDAVP-9r polyplex (1:10 mole ratio, siRNA:peptide);
and blue line: FITC-siRNA/dDAVP-9r (1:40 mole ratio, siRNA:peptide). B) Laser scanning confocal microscopic examination of the MDCK cells treated
by FITC-labeled siRNA only or FITC-labeled siRNA complexed with 9r peptides (1:10 mole ratio) or with dDAVP-9r peptides (1:10 or 1:40 mole ratio).
Nuclei of the MDCK cells were stained with DAPI. All fluorescence imaging studies were performed at least three times and images demonstrated
were representative of the majority of analyzed cells.
doi:10.1371/journal.pone.0040010.g002
Figure 3. Stability of siRNA/dDAVP-9r polyplex against RNase A, osmolality, and pH. A) siRNA (100 pmol) or siRNA/dDAVP-9r polyplex at
the various mole ratios were incubated in the absence or the presence of RNase A for 1 h or 6 h. B) siRNA/dDAVP-9r polyplex (1:10 or 1:40 mole ratio)
were incubated under different osmolalities generated by NaCl and urea or different pH levels for 60 min after formation of the polyplex. The
polyplex was incubated in the absence or the presence of 0.2% SDS, and siRNAs were electrophoresed on 2% agarose gel containing EtBr.
doi:10.1371/journal.pone.0040010.g003
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between V2R and vasopressin has been known to phosphorylate
AQP2 at S256 (PKA phosphorylation consensus site) [15,16].
As shown in Fig. 4, phosphorylated AQP2 expression (S256)
was significantly increased by the treatment of synthesized dDAVP
(Syn., Peptron Co., Ltd, Daejeon, Korea) and dDAVP-9r peptides
as well as purchased dDAVP (Sig., Sigma. St. Louis, MO) for
3 min. Importantly, siRNA/dDAVP-9r polyplex (1:10 mole ratio)
also stimulated AQP2 phosphorylation (S256) in IMCD tubule
suspension. The results demonstrate that synthesized dDAVP-9r
peptides and siRNA/dDAVP-9r polyplex could bind to V2R and
stimulate V2R signaling pathways to phosphorylate AQP2 at
S256. This could also induce the endocytosis of V2R.
Knockdown of AQP2 via V2R-mediated siRNA Delivery
Using AQP2-siRNA/dDAVP-9r Polyplex
Knockdown of AQP expression via V2R-mediated siRNA
delivery was investigated in the IMCD cells of rat kidney. For
delivering siRNA against AQP2, siRNA/dDAVP-9r polyplex
(1:10 mole ratio) was incubated in the IMCD tubule suspension for
2 h, and then IMCD tubule suspension was seeded at the 12-well
plate and cultured for 72 h. The changes of AQP2 protein
abundance was analyzed by semiquantitative immunoblotting.
AQP2 protein abundance was significantly decreased in the
primary cultured IMCD cells treated by AQP2-siRNA/dDAVP-
9r polyplex (5367%, P,0.05), compared with the cells treated by
non-target-siRNA/dDAVP-9r polyplex (Fig. 5A and B). In
contrast, AQP4 protein abundance was unchanged (8065%, not
significant (n.s.)) in the IMCD cells treated by AQP2-siRNA/
dDAVP-9r polyplex (Fig. 5A and B), indicating the specificity of
AQP2-siRNA/dDAVP-9r polyplex. The observed decrease of
AQP2 protein abundance indicates that siRNA could be
successfully transduced by dDAVP-9r peptide carrier through
V2R interaction.
Discussion
For the cell-type specific delivery of siRNA, we introduced a
novel targeting delivery system using a specific ligand to the
hormonal receptor expressed in the target cells. Recent studies
suggested that internalization of the receptor proteins after
interacting with specific ligands could facilitate the delivery of
siRNA into the target cells via receptor-mediated siRNA trans-
duction [3,17,18,19].
In the kidney, it has been established that anti-diuretic hormone
vasopressin induces internalization of V2R by clathrin-mediated
endocytosis [6,7,9,10]. To facilitate siRNA-mediated knockdown
of the targeted protein via V2R internalization, we designed
dDAVP-conjugated peptide carrier for V2R-mediated siRNA
delivery in the V2R-expressing IMCD cells. Prediction for the
structure of the synthetic peptide carrier conjugated with dDAVP
showed two separated regions (i.e., ligand domain to V2R and
siRNA carrying domain) bisected with a spacer of 4 glycines. The
nine-arginine oligopeptide, which is a-helical form, has been
known as the arginine-rich cell-penetrating peptide (CPP) for
delivering oligonucleotides into the cells [20,21,22]. This synthetic
peptide carrier made a stable polyplex with siRNA, i.e., siRNA/
dDAVP-9r polyplex at the mole ratio over 1:10 (siRNA:dDAVP-
9r). Importantly, the polyplex induces AQP2 phosphorylation at
serine 256 (PKA phosphorylation consensus site) in IMCD cells,
indicating that the polyplex could bind to V2R and stimulates
V2R. Moreover, the polyplex delivered the FITC-labeled siRNA
into the V2R-expressing MDCK cells and LLC-PK1 cells, but not
into the V2R-negative Cos-7 cells. This finding indicates that
dDAVP-conjugated peptide carrier could successfully deliver
Figure 4. Phosphorylation of AQP2 at S256 in response to dDAVP, dDAVP-9r, and siRNA/dDAVP-9r polyplex treatment in IMCD
cells of rat kidney. A) IMCD suspension was treated by dDAVP (10
28 M), dDAVP-9r peptide (10
28 M), or siRNA/dDAVP-9r polyplex (1:10) for 3 min.
B) Changes of the phosphorylated AQP2 (S256) expression relative to total AQP2 were examined by semiquantitative immunoblotting (n=4 in each
group). n, number of samples which were prepared from each well.
doi:10.1371/journal.pone.0040010.g004
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transduction. However, it should be noted that polyplex of 1:40
mole ratio possesses highly positive surface charge, leading to the
non-specific interaction with negatively charged plasma mem-
brane, as demonstrated in previous studies [13,14].
Although the mechanisms of siRNA release from peptide
carriers inside the cells have not been clearly elucidated, there are
several hypotheses to understand the process of siRNA release.
Bartz et al. reported that siRNA delivered by amphipathic peptide
was escaped from endosomes in pH-dependent manner [23].
Another hypothesis for the mechanism of siRNA release could be
achieved by the pore forming ability of arginine-rich peptides [24].
Especially, nine-arginine peptides are known to disturb the
stability of the plasma membrane significantly at low pH level
[24]. However, further studies are needed to understand the
underlying mechanisms of endosomal escape of siRNA from
peptide carriers inside the cells.
The stability of nano-particle is a critical obstacle for the
application of drug delivery. We demonstrated that the siRNA/
dDAVP-9r polyplex was stable in response to the wide range of
different osmolalities, pH levels, or to the RNases. Particularly, at
the mole ratios of 1:10 and 1:40 (siRNA:dDAVP-9r), the siRNA/
dDAVP-9r polyplex showed a stability against RNase A. Since
siRNA and nine arginine motif of the carrier forms the
hydrophobic core by electrostatic interaction [25,26], siRNA
might be protected from RNases which exist in the intracellular
vesicles during endocytosis or in the serum [27]. In the process of
internalization of siRNA/dDAVP-9r polyplex into the cells,
several factors need to be considered, including the size of the
polyplex. The adequate size of the polyplex containing ligands for
the receptor-mediated internalization is unknown, but it may be
dependent on the cell types or the endocytotic pathways. In the
case of clathrin-mediated endocytosis, however, it has been
reported that particle size might be approximately 200 nm for
efficient internalization [28]. Rejman et al. [28] showed that
microspheres with a diameter less than 200 nm was able to be
transduced into the cells by clathrin-mediated endocytosis and
delivered to the lysosomes. In contrast, microspheres with a
diameter of 500 nm were able to be internalized by caveolae-
mediated endocytosis [28]. Since V2R is mainly internalized by
clathrin-mediated internalization, the optimal size of the siRNA/
dDAVP-9r polyplex might be less than 200 nm. Another
important factor required for application of siRNA/peptide
polyplex is the capacity of their binding to the receptors. In the
present study, phosphorylation of AQP2 (S256) in rat kidney
IMCD cells was significantly enhanced by dDAVP-9r peptide as
well as siRNA/dDAVP-9r polyplex. The results indicate that
siRNA/dDAVP-9r polyplex could directly interact with V2R of
IMCD cells and stimulate the receptors. After interaction between
V2R and the polyplex, the V2R internalization could be followed,
as indicated by the observed uptake of FITC-conjugated siRNA
into the cells. Lastly, AQP2-siRNA/dDAVP-9r polyplex effec-
tively delivered siRNA into the IMCD cells, resulting in the
significant decrease of protein abundance of AQP2. In contrast,
AQP4 protein abundance was unchanged, indicating the speci-
ficity of AQP2-siRNA/dDAVP-9r. Since dDAVP could induce
V2R internalization and decrease of V2R abundance through
lysosomal degradation [9], it may be possible that this contributes
to the decrease AQP2 abundance, irrespective of siRNA action.
However, in this study, non-target-siRNA/dDAVP-9r was also
treated to the control IMCD cells in parallel with AQP2-siRNA/
dDAVP-9r treatment, and the results demonstrated the significant
decrease of AQP2 abundance selectively in the IMCD cells
treated by AQP2-siRNA/dDAVP-9r. Therefore, it is unlikely that
dDAVP-induced downregulation of the V2R contributes to the
decrease of AQP2 abundance in the IMCD cells.
In vivo application of siRNA/dDAVP-9r polyplex directly to rats
is potentially possible, since the siRNA/dDAVP-9r polyplex was
stable in the diverse environments, e.g., osmolality, pH, or
RNases. However, required doses of siRNA to induce knockdown
of target protein expression in vivo is unknown, and the effective
route of administration needs to be determined. Moreover, the
effects of dDAVP on urine concentration could be developed, if
the ratio of dDAVP-9r peptide to siRNA is high.
In summary, we, for the first time to our knowledge, introduced
a novel method of V2R-mediated siRNA delivery in the kidney
collecting duct cells using a specific peptide ligand to V2R.
siRNA/dDAVP-9r polyplex effectively delivered siRNA into the
Figure 5. Semiquantitative immunoblotting of AQP2 and AQP4 expression in primary cultured IMCD cells of rat kidney treated by
AQP2-siRNA/dDAVP-9r polyplex. A) The siRNA/dDAVP-9r polyplex (1:10) containing 200 pmol of AQP2-siRNA was incubated in the IMCD tubule
suspension for 2 h. After incubation, the cells were cultured at 12-well plate for 72 h, and then AQP protein expression was analyzed by
semiquantitative immunoblotting. B) Protein abundance of AQP2 and AQP4 in IMCD cells treated with the polyplex containing either non-target-
siRNA or AQP2-siRNA was evaluated by semiquantitative immunoblotting (n=8 in each group). *P,0.05 compared with the treatment with non-
target-siRNA; n, number of samples which were prepared from each well.
doi:10.1371/journal.pone.0040010.g005
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decrease of protein abundance of AQPs. This method could be
exploited to deliver siRNAs to regulate abnormal expression of
specific target proteins in vivo, potentially associated with disease
conditions in the kidney tubule cells expressing V2R, e.g.,
collecting duct cells and thick ascending limb cells.
Materials and Methods
Ethics Statement
This study was conducted in conformity with the principles of
the Declaration of Helsinki. Animal experiments were approved
by the Committee on the Ethics of Animal Experiments of the
Kyungpook National University (Approval Number: KNU
2011-47).
siRNAs and Peptide
All siRNAs were purchased from Dharmacon (Chicago, IL) and
dDAVP was purchased from Sigma (V1005, St. Louis, MO).
Synthetic dDAVP (Mercaptopropionyl-YFQNCPdRG-NH2) and
dDAVP-9r (Mercaptopropionyl-
YFQNCPdRGGGGGRRRRRRRRR-NH2) peptides were syn-
thesized and purified using high-performance liquid chromatog-
raphy (Peptron Co., Ltd, Daejeon, Korea). The nine- arginine
residue in the C-terminus was D-form of arginine.
Prediction of dDAVP-9r Peptide Structure
The sequence of dDAVP-9r peptide was submitted to PEP-
FOLD server [29,30,31] for peptide folding including PSIPRED
prediction [32]. PEP-FOLD is a de novo approach aimed at
predicting peptide structures from amino acid sequences. Since
PEP-FOLD is not able to treat linear peptides with D-amino acids,
L-arginine was used for modeling instead of D-arginine. N-
terminal modification with mercaptopropionic acid was also
excluded from structure calculation.
Electrophoretic Mobility Shift Assay
The siRNA/dDAVP-9r polyplex was prepared at different mole
ratios ranging from 1:0.1 to 1:10 (siRNA:dDAVP-9r). siRNA
(100 pmol) and dDAVP-9r were incubated in aqueous phase
phosphate-buffered saline (PBS 20 ml, pH 7.4) for 15 min at room
temperature (RT) for formation of polyplex. The size and size
distribution of polyplex were measured by using dynamic light
scattering of Zeta-potential & Particle size analyzer (ELS-Z,
Otzuka Electronics, Japan). The mixtures were electrophoresed on
2% agarose gel containing ethidium bromide (EtBr). To test
stability of the siRNA/dDAVP-9r polyplex against RNAase A, the
polyplex containing 100 pmol of siRNA at 1:10 and 1:40 mole
ratios of siRNA to peptides were incubated in the absence or the
presence of RNase A (0.2 mg) for 1 h or 6 h at 37uC. After
incubation, 2 ml of 2% SDS solution was added and the sample
was loaded on 2% agarose gel containing EtBr. siRNA/dDAVP-
9r polyplex was also incubated in various osmolalities produced by
NaCl and urea ranging from 0–1,200 mOsm/KgH2O for 60 min.
Concentrations of NaCl and urea to generate different osmolalities
were as follows: 0 mOsm/KgH2O (distilled H2O), 100 mOsm/
KgH2O (diluted PBS in the distilled H2O), 300 mOsm/KgH2O
(PBS), 600 mOsm/KgH2O (PBS with 150 mM NaCl and
100 mM Urea), and 1,200 mOsm/KgH2O (PBS with
400 mM NaCl and 300 mM Urea). In addition, to test the
sensitivity of polyplex to pH, siRNA/dDAVP-9r polyplex was
incubated for 60 min in various pH levels (5.5–8.0) adjusted with
HCl in PBS. The mixture was incubated with or without 0.2%
SDS and electrophoresed on 2% agarose gel containing EtBr.
Cellular Transduction of Fluorescein-labeled siRNA
Polyplex in V2R-expressing Cells
FITC-siRNA (100 pmol) and peptides were incubated for
15 min in 20 ml PBS. Cells were incubated with FITC-siRNA/
dDAVP-9r polyplex (siRNA:peptide=1:10 or 1:40 mole ratio) for
60 min at 37uC. Moreover, FITC-siRNA or FITC-siRNA/9r
peptides (siRNA:peptide=1:10) were also incubated for 60 min at
37uC, respectively. Binding of the polyplex containing FITC-
siRNA into the MDCK cells (cat. CCL-34, ATCC), LLC-PK1
cells (cat. CL-101, ATCC), and Cos-7 cells (AC28806, KCTC)
cells was examined by flow cytometry. After incubation for
60 min, cells were trypsinized and suspensed in PBS. For each
determination, the FITC intensity of 10,000 cells was measured on
the FL1 channel using a FACS Calibur flow cytometer (Becton-
Dickinson, San Jose, CA). Cytometric data was analyzed using
CELLQuest software. To access whether siRNA/dDAVP-9r
polyplex was internalized into the cells after binding to V2R,
subcellular localization was determined using laser scanning
confocal microscope (Zeiss LSM 5 EXCITER, Jena, Germany)
with a 663 (NA 1.4) objective lens (Zeiss). Digital images were
collected and analyzed using the Zeiss Aim Image Examiner
program. MDCK cells at 8-well chamber glass slides (Lab-Tek II,
Nunc, Inc., Rochester, NY) were incubated with the polyplex or
FITC-siRNA for 60 min at 37uC, and the cells were fixed with
2.5% paraformaldehyde (PFA). The nucleus was stained with
DAPI for 3 min.
Binding Assay of siRNA/dDAVP-9r Polyplex to V2R in Rat
IMCD Tubule Suspension
To investigate whether the polyplex containing peptide carriers
could stimulate V2R, phosphorylation of AQP2, which is the
target protein of vasopressin, was analyzed by immunoblot
analysis. Rat IMCD tubule suspension were prepared as a
procedure described previously [33] with few modification. The
siRNA/dDAVP-9r polyplex was prepared at the mole ratio of
1:10 (2 nmol of dDAVP-9r). dDAVP (10
28 M) alone or siRNA/
dDAVP-9r polyplex were added to 100 mL of IMCD tubule
suspension and incubated 3 min at RT. After incubation, IMCD
tubules were lysed with RIPA buffer (10 mM Tris-HCl,
0.15 M NaCl, 1% NP-40, 1% Na-deoxycholate, 0.5% SDS,
0.02% sodium azide, 1 mM EDTA, pH 7.4) containing protease
and phosphatase inhibitors (0.4 mg/ml leupeptin, 0.1 mg/ml
pefabloc, 1 mM Na3VO4, 25 mM NaF, and 0.1 mM okadaic
acid).
Protein Knockdown Assay Using siRNA/dDAVP-9r
Polyplex in Primary Cultured Rat Kidney IMCD Cells
IMCD tubule suspensions were incubated with siRNA/
dDAVP-9r polyplex containing siRNA (200 pmol) for 2 h at
37uC with gentle shaking. Then, tubules were seeded on the 12-
well plate and incubated for 72 h at 37uC. After incubation, the
cells were lysed by RIPA buffer containing protease and
phosphatase inhibitors for semiquantitative immunoblotting.
Semiquantitative Immunoblotting
Immunoblot analysis was performed as previously described
[34]. Total protein concentrations were measured by BCA assay
kit (Pierce, Rockford, IL) and all samples were adjusted with RIPA
buffer to reach the identical final protein concentrations and
solubilized at 65uC for 15 min in Laemmli sample buffer, and then
stored at 4uC. SDS-PAGE was performed on 12% polyacrylamide
gel, as previously described [34,35]. The densitometry values for
V2R-Targeting siRNA Delivery
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normalized to facilitate comparisons.
Statistical Analysis
Values are presented as means 6 SE. Comparisons between
two groups were made by unpaired t-test. Comparisions more
than two groups were made by one-way ANOVA followed by
Tukey HSD’s multiple-comparisons test. Multiple-comparisons
tests were only applied when a significant difference was
determined in the ANOVA (P,0.05). P values ,0.05 were
considered significant.
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